|  | Testosterone | DHT | ||||
---|---|---|---|---|---|---|---|
Route of administration | Number of studies | Pre-treatment T (nmol/L) (95% CI) | Post-treatment T (nmol/L) (95% CI) | Pre-Post treatment fold increase in T (95% CI) | Pre-treatment DHT (nmol/L) (95% CI) | Post-treatment DHT (nmol/L) (95% CI) | Pre-Post treatment fold increase in DHT (95% CI) |
Intramuscular | 8 | 9.27 (5.68 to 12.85) | 23.11 (15.38 to 34.72) | 2.91 (2.19 to 3.86) | 1.02 (0.69 to 1.34) | 1.62 (1.2 to 2.19) | 2.20 (1.74 to 2.77) |
Transdermal (patch and gel) | 20 | 7.28 (6.09 to 8.42) | 16.69 (12.62 to 21.98) | 2.53 (1.83 to 3.50) | 0.99 (0.78 to 1.20) | 3.43 (2.37 to 4.98) | 5.46 (4.51 to 6.60) |
Gel | 13 | 8.90 (7.67 to 10.13) | 18.3 (15.18 to 23.12) | 1.98 (1.70 to 2.30) | 1.19 (0.93 to 1.46) | 3.81 (2.57 to 5.63) | 5.12 (4.07 to 6.45) |
Patch | 7 | 4.20 (2.78 to 5.23) | 9.73 (4.01 to 23.62) | 4.43 (2.99 to 6.54) | 0.62 (0.36 to 0.88) | 2.16 (0.68 to 6.87) | 6.61 (3.08 to 14.16) |
Orala | 4 | 6.66 | 21.88 | 2.80 | 0.90 | 3.92 | 4.46 |
(14.05, 2.9, 5.6, 4.1) | (59.2, 5.70, 7.6, 14.96) | (4.20, 2.20, 1.4, 3.6) | (1.1, 1.8, 0.30, 0.41) | (9.89, 3.30, 1.13, 1.35) | 9.0, 1.8, 3.8, 3.3 |